Heartseed, a Tokyo-based biotech start-up specializing in treatments that use cardiac muscle cells to initiate the remuscularization of patients who have suffered heart failure, has raised JPY 2bn (USD 14.3m) in Series D funding.
New investors in the round included a co-investment fund managed by Sumitomo Mitsui Trust Investment, the corporate VC arm of Koei Tecmo Holdings, a Southeast Asia fund managed by hedge fund Arcus Investment,...
Novo Tellus Capital Partners, an investor in industrial technology assets across the Indo-Pacific region, has reached a first close of approximately USD 375m on its third fund – matching the overall target for the vehicle.
Matrix Partners China and HongShan (formerly Sequioa Capital China) have joined a USD 16m pre-Series B round for Qihan Biotech, a genome editing player active in human and agricultural therapies.
Trifecta Capital has closed its third India venture debt fund with about INR 17.8bn (USD 214) in commitments. The initial target was INR 10bn with a greenshoe option of INR 5bn.
Asia-focused industrial technology investor ShawKwei & Partners has announced its third investment in a US-based company in three weeks, with a USD 34.3m commitment to battery manufacturer Group14 Technologies.